Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Theravance Biopharma, Inc.NASDAQ: TBPH

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $1.44M fell 87.5% year over year, behind the -46.3% change in trailing-twelve-month cost of revenue. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at -55.7% a year.

Context

  • Cost of revenue amounted to 5.1% of revenue in FY2025, down 53.3 pp from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -87.5% toward the trailing-twelve-month pace of -46.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.44M-4.6% QoQ
Last fiscal yearDec 2025
$5.52M-85.3% YoY
LTMMar 2026
$21.55M-46.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-87.5%——
1 year-85.3%——
3-year CAGR-55.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
5.52M USD
Year-over-year change
-85.3%
4-year CAGR
-58.9%

Cost of Revenue vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -46.3% is the 6th highest of 7, against a peer median of +10.2%.
  • Cost of revenue amounts to 19.6% of revenue for TBPH, versus a peer median of 13.4%.
TBPH Competitors
Cost of Revenue for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VALNValneva SELTM Mar 2026€110.28M EUR+10.9%-30.9%70.5%
GERNGeron CorporationLTM Mar 2026$26.3M USD+968.3%—13.4%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$21.55M USD-46.3%-55.7%19.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$2.03M USD-1.5%—4.7%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$1.86M USD+5055.6%—8.8%
REPLReplimune Group, Inc.LTM Dec 2025$848K USD———
TYRATyra Biosciences, Inc.LTM Mar 2026$138K USD+9.5%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
VIRVir Biotechnology, Inc.LTM Mar 2026-$114.78M USD-122.6%-73.4%175.2%
Peer median (excluding TBPH) —+10.2%-52.1%13.4%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.